LARS1 and urinary bladder cancer: To sum up, based on the results of our analysis – certain CXC and CC chemokines are significantly upregulated in bladder cancer patients with high levels of expression of CLRs and differentially expressed immune cells and immune-checkpoint molecules in the tumor microenvironment – we hypothesize that CLRs may also modulate immune functions through the regulation of chemokines in the tumor microenvironment in bladder cancer.